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OBJECTIVES The goal of this study was to examine the implications of the pressure-derived collateral flow
index (CFIp) in acute myocardial infarction (AMI).
BACKGROUND Higher CFIp is associated with less severe myocardial ischemia during angioplasty in the
non-infarcted heart. It remains unknown whether CFIp also identifies collateral function in
AMI patients with and without no-reflow phenomenon.
METHODS The study population included 48 patients with a first AMI. After successful percutaneous
transluminal coronary angioplasty (PTCA) stent, we measured mean aortic pressure (Pa),
central venous pressure (Pv) and coronary wedge pressure (Pcw) of the infarct-related artery
to calculate: CFIp  (Pcw  Pv)/(Pa  Pv). Myocardial contrast echocardiography (MCE)
was performed with the intracoronary injection of microbubbles to assess myocardial
perfusion. Left ventriculograms at days 1 and 28 were provided for the measurement of the
regional wall motion (RWM, SD/chord).
RESULTS There was no difference in CFIp among subsets based on angiographic collateral grades (grade
0, 1, 2, 3; 0.28  0.07, 0.27  0.09, 0.27  0.08, 0.23  0.08, p  NS). The CFIp was
significantly higher in patients with MCE no-reflow (n  16) than in those with MCE reflow
(n  32) (0.34  0.07 vs. 0.23  0.06, p  0.01). There was a significant inverse correlation
between the extent of functional improvement (RWM[28 d1 d]) and CFIp (r  0.56, p 
0.01), implying that higher CFIp is associated with worse functional improvement.
CONCLUSIONS In AMI, CFIp is unlikely to reflect collateral function but seems to increase with the severity
of microvascular dysfunction. Because higher CFIp was associated with poorer functional
recovery, it provides a simple and useful estimate of clinical outcomes in AMI. (J Am Coll
Cardiol 2001;38:1383–9) © 2001 by the American College of Cardiology
Coronary reperfusion therapy with thrombolysis and/or
percutaneous coronary intervention (PCI) has brought ben-
eficial clinical outcomes in patients with acute myocardial
infarction (AMI). The beneficial impact of coronary reper-
fusion, however, varies among patients (1–5). Several factors
have been postulated to account for the variation, which
include age, elapsed time from symptom onset to reperfu-
sion, preinfarction angina and collateral channels (3–8).
Collateral channels are usually assessed with coronary an-
giography, but we may not necessarily evaluate most collat-
eral networks in the myocardium (9). Recently, several
studies have reported that the intracoronary pressure mea-
surements with pressure wire allow us to assess collateral
function in the non-infarcted heart (10–13). Pressure-
derived collateral flow index (CFIp) is hypothesized to
increase with an increase in collateral flow, and the higher
CFIp is associated with the less severe myocardial ischemia
during PCI. Likewise, higher CFIp in TIMI (Thrombolysis
In Myocardial Infarction trial)-3 flow AMI patients was
associated with better functional outcomes (14). These
findings were not identified in patients with AMI with
no-reflow or TIMI-2 reflow despite much evidence show-
ing that the microvascular dysfunction is common in pa-
tients with AMI (15–21).
This study was designed to assess whether CFIp reflects
collateral function in patients with AMI under the presence
of microvascular dysfunction. We assessed the severity of
microvascular dysfunction with both myocardial contrast
echocardiography (MCE) and TIMI flow grade and studied
the relation between no-reflow phenomenon and CFIp.
Finally, we assessed the clinical value of the new pressure-
derived index in assessing functional outcomes in patients
with reperfused AMI.
METHODS
Study population. We prospectively studied 52 patients
with first AMI, referred to our hospital between January
2000 and October 2000, who met the following criteria: 1)
chest pain 30 min in duration and presentation 24 h
after the symptom onset; 2) ST segment elevation 2 mm
in at least two electrocardiograph (ECG) leads; 3) 3-fold
increase in serum creatine kinase; 4) TIMI-0 or -1 flow at
baseline study; 5) successful coronary reflow (residual diam-
eter stenosis 25%) after the primary PCI; and 6) under-
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going MCE study shortly after PCI. Exclusion criteria were
the presence of cardiogenic shock, previous bypass surgery,
moderate-to-severe valvular lesions, atrial fibrillation and
recurrent ischemic events during the follow-up period. Four
patients were excluded: three because of severe congestive
heart failure and one because of reinfarction during follow-
up. Thus, 48 patients were enrolled in this study. The study
protocol was approved by the ethics committee of our
hospital, and written informed consent was obtained from
all patients before cardiac catheterization by one of the
investigators.
Protocols. We gave aspirin (243 mg) to each patient.
Following intravenous (IV) heparin (100 U/kg), we per-
formed left and right coronary angiography and left ven-
triculography (right anterior oblique view) using the right
femoral approach with the Judkins’ technique. We per-
formed primary PCI according to the protocol of our
hospital to achieve residual diameter stenosis of 25%. A
0.0014-in. (0.036 cm) fiber optic pressure monitoring guide
wire (Wave Wire, Endo Sonics, Rancho Cordova, Califor-
nia) was set at 0, calibrated, advanced through the guiding
catheter and positioned distal to the culprit lesion. After
intracoronary injection of 0.3 mg nitroglycerin, the culprit
lesion was occluded by the inflated balloon to measure distal
coronary pressure. We simultaneously measured mean aortic
pressure (Pa) (mm Hg, via the guiding catheter), the distal
coronary artery wedge pressure during balloon occlusion
(Pcw) (mm Hg) and central venous pressure (Pv). The
CFIp (unitless) was calculated as (PcwPv) divided by
(PaPv).
At a mean of 16 min after PCI, we injected 2 ml of
sonicated Ioxaglate (Hexabrix-320, Tanabe) containing mi-
crobubbles of a mean size of 12 m into the right or left
coronary artery, whichever included the infarct lesion, to
study the contrast reperfusion pattern (19–21). Echocardio-
grams were monitored using a mechanical sector scanner
(SONOS100, Agillent Technologies, carrier frequency of
3.5 MHz). The MCE images were recorded on SVHS
videotape (AG-6300, Panasonic); MCE images included
the parasternal short-axis view at the mid-papillary muscle
level and the apical two-chamber and four-chamber views.
Coronary angiography and left ventriculography were also
performed at a mean of 28 days after PCI.
Evaluation of angiographic data. Angiographic collateral
grade was determined by two independent observers accord-
ing to Rentrop’s classification (22). These observers also
evaluated TIMI flow grade of the infarct-related artery at
days 1 and 28 (23). The global left ventricular ejection
fraction (LVEF) was measured with the area–length
method and regional wall motion (RWM) with the center-
line method all by the same physician, who had no knowl-
edge of the patient’s data (24). Both LVEF and RWM
were calculated as the difference of the values at day 28
minus those at day 1.
Assessment of myocardial perfusion abnormalities.
Echocardiograms were analyzed with a commercially avail-
able off-line computer system (Color Cardiology Worksta-
tion, TomTec Imaging). The details of analysis were de-
scribed elsewhere (19–21). An operator who did not know
the patients’ data analyzed the MCE images. We used the
apical two-chamber view and the parasternal short-axis view
for an anterior wall AMI and for an inferior or posterior wall
AMI, respectively. The area at risk was defined as an area of
akinesia or dyskinesia at baseline study. Myocardial reper-
fusion in the risk area was considered incomplete (MCE
no-reflow) when the endocardial length of contrast perfu-
sion defect exceeded a quarter of that of the risk area. In the
other cases, we considered myocardial reperfusion adequate
(MCE reflow). Areas showing contrast defect were always
successfully defined, and measurements of the size of
contrast defects were highly reproducible (21).
Statistical analysis. Statistical analysis was performed us-
ing StatView 5.0 for Macintosh. Continuously distributed
variables were expressed as mean  SD. The one-way
analysis of variance (ANOVA) with the Fisher PLD test
was used to compare continuous variables, and the chi-
square test was used to compare categorical variables.
Receiver operating characteristic curves were constructed to
study the feasibility of parameter for predicting MCE
no-reflow. Multiple regression analysis was performed to
identify independent factors those were related to CFIp. A
p value 0.05 was considered statistically significant.
RESULTS
Angiographic collateral grade and CFIp. There was no
difference in CFIp among those with collateral grades of 0
to 3 (grades 0, 1, 2, 3; 0.28  0.07, 0.27  0.09, 0.27 
0.08, 0.23  0.08, p  NS), and there was no relation
between CFIp and the collateral grade (Fig. 1). There was
also no difference in CFIp between the patients with no or
poor collateral (grade 0 or 1) and those with well-developed
collateral (grade 2 or 3) (0.28 0.08 vs. 0.26 0.08, pNS).
The CFIp and microvascular injury. The study popula-
tion was divided into two groups according to contrast
reperfusion pattern: MCE no-reflow (n  16) and MCE
reflow (n  32) (Table 1). The MCE reflow group had
better angiographical collateral than those with MCE no-
reflow. There were no differences in other baseline charac-
Abbreviations and Acronyms
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CFIp  pressure-derived collateral flow index
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1384 Yamamoto et al. JACC Vol. 38, No. 5, 2001
Implication of Collateral Flow Index in AMI November 1, 2001:1383–9
teristics between the two groups. There was also no differ-
ence in hemodynamic variables between the two groups
except for left ventricular end-diastolic pressure (LVEDP),
which was higher in the MCE no-reflow group than in the
MCE reflow group.
The CFIp was significantly higher in the MCE no-reflow
than in the MCE reflow group. Although Pa and Pv were
comparable between the two groups, the mean Pcw was
significantly higher in the MCE no-reflow than in the
MCE reflow group. Thus, the elevation of mean Pcw seems
in part to explain an increase in CFIp in the MCE
no-reflow patients. Figure 2 compares the instantaneous
waveform of Pcw in patients with MCE no reflow and those
with MCE reflow. Diastolic Pcw showed comparable val-
ues, but systolic Pcw was higher in patients with MCE
no-reflow than in patients with MCE reflow. Although
there was no difference in end-diastolic Pcw between the
two groups, peak systolic Pcw was significantly higher in the
MCE no-reflow than in the MCE reflow group (Fig. 3).
These findings clearly show that an increase in mean Pcw is
attributable mainly to an increase in systolic Pcw in MCE
no-reflow.
Multiple regression analysis was performed to identify the
factors that are closely related to CFIp. These included
heart rate, LVEDP, LVEF, RWM, angiographical collat-
eral grade, infarct-related artery, time interval from the
symptom onset to reperfusion, heart rate and the presence
or absence of MCE no-reflow. Among these factors, MCE
no-reflow and LVEDP are the independent factors related
to CFIp (t value 4.5 vs. 2.4, p value 0.01 vs. 0.05,
respectively), and MCE no-reflow showed the strongest
relationship to the CFIp. Receiver operating characteristic
analysis documented that we can estimate MCE no-reflow
with sensitivity of 93% and specificity of 75% by CFIp of
0.26.
The CFIp and functional outcomes. All patients showed
patent infarct-related artery without restenosis and also
showed TIMI flow grade 3 (Table 2). Peak creatine phos-
phokinase was significantly higher in the MCE no-reflow
than in the MCE reflow group. The values for LVEF and
RWM at both days 1 and 28 were significantly higher in the
MCE reflow group than in the MCE no-reflow group, and
LVEF and RWM were also higher in the MCE reflow
group than in the MCE no-reflow group. We compared the
relation between CFIp and magnitude of improvement in
left ventricular function. The CFIp significantly correlated
with RWM (Fig. 4A) and LVEF (r  0.42, p  0.01),
implying the higher CFIp is associated with worse func-
Figure 1. Comparison of pressure-derived collateral flow index (CFIp)
among angiographical collateral grades. There was no difference in CFIp
among collateral grades (0, 1, 2, 3; 0.28  0.07, 0.27  0.09, 0.27  0.08,
0.23  0.08, p  NS), and a correlation was not found between the two
variables. Values are expressed as mean  SD.
Table 1. Patient Characteristics and Coronary Hemodynamic Variables
MCE Findings
p
Value
No Reflow
(n  16)
Reflow
(n  32)
Age (yrs) 62  9 58  11 NS
Male gender 14 (88) 26 (81) NS
Anterior wall AMI 14 (88) 17 (53) NS
Onset-reperfusion time (h) 6.8  6.3 5.6  5.0 NS
Good collaterals 5 (31) 25 (70)  0.05
%-Diameter stenosis after PTCA 10  8 10  10 NS
Smoking 10 (63) 20 (63) NS
Hypercholesterolemia 7 (44) 15 (47) NS
Diabetes mellitus 5 (31) 7 (22) NS
Hypertension 6 (37) 14 (44) NS
Pa, mm Hg 90  21 95  13 NS
Heart rate, beats/min 85  14 79  14 NS
LVEDP, mm Hg 17  6 11  5  0.05
Pv, mm Hg 7  3 5  3 NS
Pcw, mm Hg 35  9 26  5  0.01
CFIp 0.34  0.07 0.23  0.06  0.01
Parameters are expressed as mean  SD and number (percent).
CFIp  pressure-derived collateral flow index; good collateral  Rentrop grade 2 or 3; Pa  mean aortic pressure; Pcw 
coronary wedge pressure; Pv  central venous pressure.
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tional improvement. All patients with MCE reflow had
TIMI-3 reflow. Among 16 patients with MCE no-reflow,
10 patients showed TIMI-2 reflow, and six patients showed
TIMI-3 reflow. When CFIp and RWM were compared
with each other in the selected patients with MCE reflow or
TIMI-3 reflow, there was no relation among the patients
with MCE reflow, but there was a weak inverse correlation
among those with TIMI-3 reflow (MCE reflow; r  0.32,
p  NS, TIMI-3 reflow; r  0.50, p  0.01).
Because a good correlation existed between CFIp and
RWM in the patients with AMI, we derived a simple
parameter that does not require the measurement of Pv to
estimate functional outcomes: Pcw/Pa. This parameter was
significantly lower in the MCE reflow group than in the
MCE no-reflow group (0.28  0.04 vs. 0.39  0.07, p 
0.01). The receiver operating characteristics curve docu-
mented that MCE no-reflow could be recognized with
sensitivity of 100% and specificity of 78% by Pcw/Pa of
0.30. There was a close inverse relation between Pcw/Pa
and RWM (Fig. 4B).
DISCUSSION
Our study documented that pressure-derived collateral flow
index (CFIp) does not necessarily reflect collateral function
in patients with AMI. In other words, the higher CFIp does
not imply the presence of angiographically well-developed
collateral channels nor is it associated with better functional
improvement. The CFIp was even higher in patients with
MCE no-reflow than in those with MCE reflow, and the
higher CFIp was associated with worse functional improve-
ment. Thus, the CFIp is significantly influenced by the
presence and severity of ischemic microvascular dysfunction
in AMI, and the higher CFIp is associated with no-reflow
phenomenon and with the worse functional outcomes.
Figure 2. Waveforms of aortic pressure (Pa) and coronary wedge pressure (Pcw) in patients with MCE reflow (A) and with MCE no-reflow (B). Although
Pcw shows comparable value in diastole, Pcw was extremely higher in systole in a case of MCE no-reflow than in a case of MCE reflow.
Figure 3. Comparison of peak systolic Pcw (A) and end-diastolic Pcw (B) between the patients with MCE reflow and those with MCE no-reflow. There
was no difference in end-diastolic Pcw between the two groups, but peak systolic Pcw was significantly higher in patients with MCE no-reflow than in those
with MCE reflow (end-diastolic pressure: 22  10 vs. 18  4, NS; peak systolic pressure: 59  11 vs. 40  13, p  0.01). Abbreviations as in Figure 2.
Values are expressed as mean  SD.
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The CFIp and microvascular dysfunction in AMI. Our
result is different from the previous observation that implies
the CFIp parallels the functional significance of total
collateral channels in the non-infarcted heart (10–13). This
difference is explained by the presence of the microvascular
dysfunction in the infarct zone. In the non-infarcted heart,
the pressure signals obtained distal to the occluded coronary
artery almost invariably originated from collateral channels.
Hence, an increase in Pcw is caused mainly by collateral
flow, and thus, CFIp is a likely index to express the amount
of flow to the vascular region of interest as a fraction of the
flow via the collateral channels. Acute myocardial infarction
is a different case. The higher CFIp is not associated with
well-developed collateral channels. From the analysis of
instantaneous waveform of Pcw, we found that the elevation
of systolic Pcw seems to be a main reason for an increase in
mean Pcw.
Increase in systolic Pcw, especially in patients with
reperfused but no-reflow AMI, may be explained by the
congested blood flow in coronary microvasculature. In the
non-infarcted heart, intramyocardial blood is smoothly
squeezed into the venous circulation in systole, but this
ejection of blood to the venous system should be impeded
owing to the extensive microvascular obstruction in the
infarct zone. Because of this congestion, intramyocardial
blood pressure should increase extremely in systole with an
increase in myocardial wall stress. Another possible expla-
nation of the increase in systolic Pcw in MCE no-reflow is
that the systolic pressure wave comes from open collaterals
entering the infarct vessels distally of the balloon and
proximally to the microvessels. Because of the congestion of
the distal infarct vessels, collateral flow may experience a
no-reflow problem. These open collaterals, not visible an-
giographically, could be the reason for an elevated systolic
post-balloon pressure. Thus, an increase in systolic Pcw and
CFIp is hypothesized to be dependent on the increase in the
impedance of the microvasculature. In fact, these variables
were higher in the MCE no-reflow than in MCE reflow
group. In this sense, CFIp can be regarded as an alternate
means of estimating microvascular dysfunction and func-
tional outcomes in AMI.
Difference from previous studies. Choel et al. (14) studied
the clinical implications of CFIp in patients with reperfused
AMI and documented the better functional outcomes asso-
Figure 4. Correlation between RWM and CFIp (A) and Pcw/Pa (B). There was significant inverse correlation between RWM and CFIp (A). Thus,
the higher CFIp is associated with the lower RWM, implying the worse functional outcomes. Significant correlation was also found between RWM
and Pcw/Pa (B). This correlation coefficient seems to be better than that between CFIp and RWM. Solid circles indicate patients with MCE no-reflow,
and open circles represent patients with MCE reflow.   the difference of the values at day 28 minus those at day 1. Other abbreviations are the same
as before.
Table 2. TIMI Flow Patency and Function of Left Ventricle
MCE Finding
p
Value
No Reflow
(n  16)
Reflow
(n  32)
TIMI-2 10 (62) 0 (0)  0.01
TIMI-3 6 (38) 32 (100)  0.01
Peak CK, IU/l 5,440  2,010 2,230  1,300  0.01
LVEF at day 1 (%) 42  12 52  10  0.05
LVEF at day 28 (%) 44  15 63  11  0.01
LVEF (%) 2  10 10  9  0.01
RWM at day 1 (%) 3.19  0.48 2.92  0.60 NS
RWM at day 28 (%) 2.99  0.65 1.59  0.77  0.01
RWM (%) 0.20  0.38 1.32  0.85  0.01
Values are expressed mean  SD and number (percent).
CK  creatine kinase; LVEF  left ventricular ejection fraction; MCE  myocardial contrast echocardiography; RWM 
regional wall motion; TIMI  Thrombolysis In Myocardial Infarction.
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ciated with patients with higher CFIp. Their result was
different from our observations. Their study population
included only patients with TIMI-3 reflow after successful
percutaneous transluminal coronary angioplasty. In contrast,
our study included patients with successful coronary recan-
alization irrespective of TIMI flow grades. Among our
patients, 33% and 21% showed MCE no-reflow and
TIMI-2 reflow, respectively. Therefore, their finding is
exclusively based on patients with only minimally damaged
microvasculature, rather than on common AMI patients.
We compared CFIp and RWM in selected patients
with TIMI-3 reflow, but we found only a weak inverse
correlation between the two variables. Although the number
of patients was small compared to the Choel et al. study,
this result should indicate that the microvascular dysfunc-
tion cannot be negligible even in patients with TIMI-3
reflow. Our previous study demonstrated that 16% of
patients with reperfused and TIMI-3 reflow AMI showed
sizable no-reflow phenomenon (18). Our MCE study also
documented that contrast intensity in the risk area, which
parallels functional microvasculature, decreased in patients
with AMI (19). Thus, CFIp seems to be affected by the
microvascular dysfunction even in patients with reperfused
and TIMI-3 reflow AMI.
Study limitations. Our findings are derived from a selected
population of AMI patients who were successfully treated
with primary PCI. Patients with shock, hemodynamically
instability or recurrent myocardial infarction were excluded
from the study because the CFIp is difficult to obtain.
Hence, our results may not be generalizable to all patients
receiving reperfusion therapy.
We evaluated collateral status after PCI, although an-
giography for evaluating collateral status was done before
PCI. Microembolization with obstruction of the peripheral
microvasculature may possibly occur with PCI (25). Hence,
collateral channels angiographically proven before PCI
might disappear after PCI because of the congestion of
blood flow within the no-reflow zone. Thus, evaluated
collateral status before PCI does not necessarily correspond
with functional state after PCI is performed.
Based on our data, we hypothesized that the higher Pcw
is caused by extensive microvascular dysfunction. The
higher Pcw, however, is likely to reflect simply larger
infarctions associated with no-reflow, higher LVEDP and
poor contractile function rather than being specific for
microvascular dysfunction. Experimental studies are re-
quired to reveal the relation between Pcw and the severity of
microvascular dysfunction.
Clinical implications. The method described in the
present study can be routinely applied in clinical practice
with standard equipment and with minimal prolongation of
the procedural time. For calculating CFIp, only an additional
central venous catheter is required; but the measurement of
central venous pressure is not necessary to assess functional
outcomes. Pcw/Pa shows a reasonable correlation with func-
tional improvement. The procedure to measure Pcw/Pa is easy
and safe, and thus, Pcw/Pa provides a useful estimate of
functional outcomes in patients with reperfused AMI.
Acknowledgment
We gratefully acknowledge the excellent secretarial assis-
tance of Hideko Masuda.
Reprint requests and correspondence: Dr. Hiroshi Ito, Division
of Cardiology, Sakurabashi Watanabe Hospital, 2-4-32 Umeda,
Kita-ku, Osaka 530-0001, Japan. E-mail: itomd@osk4.3web.ne.jp.
REFERENCES
1. Harzler GO, Rutherford BD, McConahay DR, et al. Percutaneous
transluminal coronary angioplasty with and without thrombolytic
therapy for treatment of acute myocardial infarction. Am Heart J
1983;106:965–73.
2. GISSI (Gruppo Italiano per lo Studio della Stetochinasi nell’Infarto
miocardico infarction). Effectiveness of intravenous thrombolytic
treatment in acute myocardial infarction. Lancet 1986;1:397–401.
3. ISAM Study Group. A prospective trial of Intravenous Streptokinase
in Acute Myocardial Infarction (ISAM): mortality, morbidity and
infarct size at 21 days. N Engl J Med 1986;314:1465–71.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative
Group. Randomized trial of intravenous streptokinase, oral aspirin,
both or neither among 17,187 cases of suspected acute myocardial
infarction: ISIS-2. Lancet 1988;2:349–60.
5. Passamani E, on behalf of the TIMI study group. The Thrombolysis
in Myocardial Infarction (TIMI) trial. N Engl J Med 1985;312:932–6.
6. Gohlke H, Heim E, Roskamm H. Prognostic importance of collateral
flow and residual coronary stenosis of the myocardial infarct artery
after anterior wall Q-wave acute myocardial infarction. Am J Cardiol
1991;67:1165–9.
7. Habib GB, Heibig J, Forman SA, et al. Influence of coronary
collaterals on myocardial infarct size in humans: result of phase 1
Thrombolysis in Myocardial Infarction (TIMI) trial. Circulation
1991;83:739–46.
8. Sabia PJ, Powers ER, Jayaweera AR, et al. Functional significance of
collateral blood flow in patients with recent acute myocardial infarc-
tion: a study using myocardial contrast echocardiography. Circulation
1992;85:2080–9.
9. Gensini GG, daCosta BCB. The coronary collateral circulation in
living man. Am J Cardiol 1969;24:393–400.
10. Pijls NHJ, Bech JW, El Gamal HJH, et al. Quantification of
recruitable coronary collateral blood flow in conscious human and its
potential to predict future ischemic events. J Am Coll Cardiol
1995;25:1552–8.
11. Pijls NHJ, Van Son JMA, Kirkeceeide RL, et al. Experimental basis of
determining maximum coronary, myocardial and collateral blood flow
by pressure measurements for assessing functional stenosis severity
before and after percutaneous transluminal coronary angioplasty.
Circulation 1993;87:1354–67.
12. Seiler C, Fleish M, Garachemani A, et al. Coronary collateral
quantitation in patients with coronary artery disease using intravascular
flow velocity or pressure measurements. J Am Coll Cardiol 1998;32:
1272–9.
13. Van Liebergen RAM, Pick JJ, Koch KT, et al. Quantification of
collateral flow in humans: a comparison of angiographic, electrocar-
diographic and hemodynamic variables. J Am Coll Cardiol 1999;33:
670–9.
14. Choel WL, Seong-Wook P, Seung-Jung P, et al. Pressure-derived
fractional collateral blood flow: a primary determinant of left ventric-
ular recovery after reperfused acute myocardial infarction. J Am Coll
Cardiol 2000;35:945–55.
15. Schofer J, Montz R, Mathey DG. Scintigraphic evidence of the ‘no
reflow’ phenomenon in human beings after coronary thrombolysis.
J Am Coll Cardiol 1985;5:593–8.
16. Bates ER, Krell MJ, Dean EN, O’Neill WW, Vogel RA. Demon-
stration of the ‘no reflow’ phenomenon by digital coronary arteriogra-
phy. Am J Cardiol 1986;57:177–8.
1388 Yamamoto et al. JACC Vol. 38, No. 5, 2001
Implication of Collateral Flow Index in AMI November 1, 2001:1383–9
17. Nicklas JM, Diltz EA, O’Neil WW, Bourdillon PDV, Walton JA Jr,
Bertram P. Quantitative measurement of coronary flow during medical
revascularization (thrombolysis or angioplasty) in patient with acute
infarction. J Am Coll Cardiol 1987;10:284–9.
18. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns
related to thrombolysis in myocardial infarction perfusion grades after
coronary angioplasty with acute anterior wall myocardial infarction.
Circulation 1996;93:1993–9.
19. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion
immediately after successful thrombosis: a predictor of poor recovery of
left ventricular function in anterior myocardial infarction. Circulation
1992;85:1699–705.
20. Ito H, Maruyama A, Iwakura K, et al. Clinical implication of the ‘no
reflow’ phenomenon: a predictor of complications and left ventricular
remodeling in reperfused anterior wall myocardial infarction. Circula-
tion 1996;93:223–8.
21. Ito H, Tomooka T, Sakai N, et al. Time course of functional
improvement in stunned myocardium in risk area in patients with
reperfused anterior infarction. Circulation 1993;87:355–62.
22. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral
channel filling immediately after controlled coronary artery occlusion
by an angioplasty balloon in human subjects. J Am Coll Cardiol
1985;5:587–92.
23. Chesebro JH, Knatterud G, Robert R, and the TIMI Investigators.
Thrombolisis in Myocardial Infarction (TIMI) trial, phase I: a
comparison between intravenous plasminogen activator and intrave-
nous streptokinase. Circulation 1987;76:142–54.
24. Sheehan FH, Stewart DK, Dodge HT et al. Variability in the
measurement of regional left ventricular wall motion from contrast
angiogram. Circulation 1983;68:550–9.
25. Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol
2000;36:22–4.
1389JACC Vol. 38, No. 5, 2001 Yamamoto et al.
November 1, 2001:1383–9 Implication of Collateral Flow Index in AMI
